ArticleFrontiers in pediatrics2026
Transfusion practices, thresholds, and complications in pediatric oncology patients: a single-center prospective longitudinal observational study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the frequency, indications, pre-transfusion threshold values, associated risk factors, and complications of blood product transfusions in pediatric oncology patients to contribute to the development of evidence-based, standardized transfusion strategies. This single-center, prospective observational study included 41 pediatric oncology patients aged 1 to 18 years who received red blood cell (RBC), platelet, or fresh frozen plasma (FFP) transfusions between June 2023 and June 2024. Patients were followed throughout their treatment and for six months after their final transfusion. Among 404 transfusions (215 RBC, 183 platelet, 6 FFP), the mean number per patient was 9.78 ± 9.2. Pre-transfusion platelet thresholds were significantly higher in the leukemia/lymphoma group than in the solid tumor group (23,892 ± 11,773/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.